Jaguar Health, Inc. (NASDAQ:JAGX) shares are trending on Tuesday night.

Shares of the San Francisco-based biopharmaceutical company jumped 5.19% to $36.25 in after-hours trading, following the Food and Drug Administration’s decision to waive key prescription drug fees for two of its therapies.

FDA Waives Fees On HIV/AIDS Drug

Napo Pharmaceuticals, Jaguar Health’s family company, said the FDA granted a waiver of the Prescription Drug User Fee Act fee for Mytesi crofelemer delayed-release tablets for fiscal year 2027, the company announced Tuesday. Mytesi is approved for symptomatic relief of noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy and is commercialized in the U.S. by Michigan-based pharmaceutical and nutraceutical packager and manufacturer Future Pak, LLC.

Separately, the FDA’s Center for Veterinary Medicine waived fees for Canalevia-CA1, Jaguar’s conditionally approved drug treating chemotherapy-induced diarrhea in dogs, also marketed by Future Pak.

Trading Metrics, Technical Analysis

Jaguar Health has a market capitalization of $13.73 million, a 52-week high of $1,280.95 and a 52-week low of $2.37. The company has approximately 345,000 shares outstanding.

The Relative Strength Index (RSI) of JAGX stands at 81.09.

The small-cap stock has fallen 96.77% over the past 12 months.

JAGX is currently trading very close to its annual low.

Price Action: The biotech stock closed the regular session on Tuesday at $34.46, up 1,190.64%, according to Benzinga Pro data.

Benzinga’s Edge Stock Rankings indicates Jaguar Health stock has a negative price trend across all time frames.

See More: Top Value Stocks

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: Zakharchuk on Shutterstock.com